We have waited, waited and waiting 15 months, regarding Striate+, American partnership, but management throw another carrot, wanting to spend more money on a bigger facility. We as investors keep getting kicked in the guts over and over again with next to zero information on these so called partnerships.
Ill give it to management, they haven’t changed one bit in the way they do business the last ten years, a little like our share price.
We all know the biotech sector is down, and may well continue to drop, but year after year I’ve herd excuse after excuse as to why Orthocell can’t gain traction in share price
Afterpay proves to me a company doesn’t have to make big money to see a return on a share price, you yourself probably made 300% on outlays. Buy now pay later has been around many 30 years before Afterpay, just captured the right audience ( investor)
The Orthocell management team just can’t seem to excite the market, do we need new management, do we need to move our West Australian base to the East Coast and set up in Sydney or Melbourne.
Leslie Wise, please give me an update on all products American, refresh my memory a little, seems your input to the company has been a waste.
As I’ve said many a time 76-80% owned by retail hasn’t helped our struggling share price, with it sold down faster, than it goes up, profit takers
The good
We should be closer to Striate+ US partnership, building a bigger facility to supply demand
Ortho-ATI, TGA approval / ready to partner up for phase 3 trials in America, FDA approvals shouldn’t be long now
Ortho-Nerve, TGA approved, A quick 30% increase, sold back down within three days. Waiting on information about FDA approval
Ortho- Rope ( ACL ) started trials on larger animals like sheep
- Forums
- ASX - By Stock
- OCC
- Ortho-ACL (Rope)
Ortho-ACL (Rope), page-32
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
Add OCC (ASX) to my watchlist
|
|||||
Last
39.5¢ |
Change
-0.005(1.25%) |
Mkt cap ! $83.73M |
Open | High | Low | Value | Volume |
40.0¢ | 40.0¢ | 39.5¢ | $9.864K | 24.82K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4241 | 39.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
40.0¢ | 203037 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 17541 | 0.395 |
2 | 12248 | 0.390 |
3 | 9000 | 0.385 |
5 | 71825 | 0.380 |
5 | 44000 | 0.375 |
Price($) | Vol. | No. |
---|---|---|
0.400 | 203037 | 5 |
0.405 | 11143 | 1 |
0.410 | 94785 | 6 |
0.415 | 3200 | 1 |
0.420 | 30636 | 3 |
Last trade - 10.32am 12/07/2024 (20 minute delay) ? |
Featured News
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
OCC (ASX) Chart |